Boardroom Alpha
Boardroom Alpha
EXC · Current Report (Form 8-K) · Filed November 24, 2025

Exelon Corp — Current Report (Form 8-K)

Form
8-K
Filed
November 24, 2025
Period
Nov 18, 2025
Ticker
EXC
Accession
0001109357-25-000192
Boardroom Alpha · Filing insights

Court grants preliminary approval of Exelon derivative settlement. Notices and the settlement agreement are attached.

About Exelon Corp
Market cap
$46.0B
1Y TSR
+7.7%
3Y TSR
+7.5%
Board grade
B-
Sector
Utilities
CEO
Calvin Butler Jr
Last annual meeting: Apr 28, 2026 · View full Exelon Corp profile →
exc-20251118

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
November 18, 2025
Date of Report (Date of earliest event reported)
Commission
File Number
Name of Registrant; State or Other Jurisdiction of Incorporation; Address of Principal Executive Offices; and Telephone NumberIRS Employer Identification Number
001-16169EXELON CORPORATION23-2990190
(a Pennsylvania corporation)
10 South Dearborn Street
P.O. Box 805379
Chicago, Illinois 60680-5379
(800) 483-3220
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
EXELON CORPORATION:
Common Stock, without par valueEXCThe Nasdaq Stock Market LLC
Indicate by check mark whether any of the registrants are emerging growth companies as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if any of the registrants have elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 7.01. Regulation FD Disclosure.

On November 18, 2025, the United States District Court for the Northern District of Illinois issued an order (the “Preliminary Approval Order”) granting preliminary approval of the proposed settlement of a consolidated stockholder derivative action captioned In re Exelon Corporation Derivative Litigation, No. 1:21-cv-03611 (N.D. Ill.) (the “Consolidated Derivative Action”). As previously disclosed, this proposed settlement of the Consolidated Derivative Action was reached through mediation efforts by the Special Litigation Committee (the “SLC”), the Independent Review Committee of the Exelon Corporation (the “Company”) Board of Directors (the “Board”) (which had been formed in 2022 to ensure the Board’s consideration of any SLC recommendations would be independent and objective), the Board, and certain of the derivative stockholders.

The terms of the proposed settlement of the Consolidated Derivative Action are set forth in the Stipulation and Agreement of Settlement, attached hereto as Exhibit 99.2 and incorporated by reference herein. Pursuant to the Preliminary Approval Order, the Company is publishing the Notice of Pendency and Proposed Settlement of Consolidated Derivative Action, attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information set forth in and incorporated by reference into this Item 7.01 of this Current Report on Form 8-K is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing. The furnishing of this Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information herein that is required to be disclosed solely by reason of Regulation FD.

Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits.
Exhibit No.Description
104Cover Page Interactive Data File (formatted as Inline XBRL)




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, each Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EXELON CORPORATION
/s/ Colette D. Honorable
Colette D. Honorable
Executive Vice President, Chief Legal Officer and Corporate Secretary

November 24, 2025




EXHIBIT INDEX
Exhibit No.Description
104Cover Page Interactive Data File (formatted as Inline XBRL)


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Exelon Corp (EXC)

Reference

Frequently asked questions

When did Exelon Corp file this 8-K?
Exelon Corp (EXC) filed this Current Report (Form 8-K) with the SEC on November 24, 2025. The accession number assigned by EDGAR is 0001109357-25-000192.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Court grants preliminary approval of Exelon derivative settlement. Notices and the settlement agreement are attached. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Exelon Corp's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Exelon Corp has filed under CIK 1109357, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer